Nonnucleoside reverse-transcriptase inhibitors (NNRTIs) can rapidly select for drug-resistant human immunodeficiency virus type 1 (HIV-1) variants, although their effect on HIV-1 quasi-species diversity is unknown. To determine if changes in env gene diversification occur with NNRTI therapy, we used the heteroduplex tracking assay (HTA) to study HIV-1 env sequence diversity in 2 groups of patients: those who were on no therapy or were on chronic antiretroviral therapy and those who had just initiated NNRTIs. Forty-nine paired samples from 46 patients were analyzed. Fourteen of 32 paired samples from the NNRTI group and 9 of 17 paired samples from the control group had HTA changes (
Human immunodeficiency virus type 1 (HIV-1) exists in patients as a quasi species, defined as a group of closely related but genetically distinct sequences [1] . The heteroduplex mobility and heteroduplex tracking assays (HTAs) are used to give an evolutionary assessment of an entire quasi species and to track representative individual genomes [2] . Both assays have been used to follow the evolution of sequences in HIV-1-infected patients [2, 3] and to determine phylogenetic relationships among related sequences [4] .
Heteroduplex assays have primarily utilized the HIV-1 env gene, which encodes the viral envelope proteins, because it has regions of high genetic variation [5] . HTA, using a 700-bp fragment encoding the V3-V5 region from env, has shown that patients are initially infected with a homogenous species that rapidly diversifies over time [2] . Diversification of HIV-1 quasi species has been shown to precede clinical progression [6] and could lead to virus escape from the immune system and antiviral therapies. Drug therapy has the potential to alter HIV-1 evolution within a patient by restricting viral diversity or by changing the composition of the quasi species.
There are 3 classes of HIV-1 reverse-transcriptase (RT) inhibitors: nucleoside analogs, nucleotide analogs, and nonnucleoside inhibitors (NNRTIs). NNRTIs bind to a hydrophobic pocket in RT [7] . NNRTIs that have been studied clinically include nevirapine; efavirenz; the bisheteroarylpiperazines delavirdine and atevirdine; L697,661; loviride; HBY 097; emivirine; and AG-1549 [8] [9] [10] . Resistance to NNRTIs is mediated by mutations in the NNRTI pocket that reduce drug binding. Resistant HIV-1 isolates can emerge rapidly, within 2-8 weeks of initiating therapy [11] . Because NNRTI therapy can have such profound effects on the genotype of the predominant replicating strain, we asked whether the emergence of HIV-1 drugresistant mutants is associated with changes in HIV-1 env quasispecies diversity.
Materials and Methods
Patient population. Patients in the NNRTI group had been enrolled in studies of NNRTI therapy at the University of Rochester and had specimens stored. Control patients were either not on therapy or had been on stable antiretroviral therapy for 16 months. All subjects who met these criteria and had stored specimens available for analysis were included in this retrospective study. We examined cultured peripheral blood mononuclear cells (PBMC) from 32 patients who were initiating NNRTI therapy and from 14 control patients. Baseline samples were obtained !1 month before initiating NNRTIs; follow-up samples were obtained 1-2 months later. All specimens from control patients were collected within a 4-month period. Plasma HIV-1 RNA concentration. Plasma HIV-1 RNA concentration was determined with the Amplicor HIV-1 Monitor assay (Roche Diagnostic Systems, Branchburg, NJ). The linear range of this assay is 400-750,000 copies/mL. Values below and above this range were set equal to these lower and upper limits, respectively. Proviral DNA amplification. Proviral DNA was isolated from PBMC stored at the termination of HIV culture with the QIAamp blood kit (Qiagen, Chatsworth, CA). The V3-V5 region of env was amplified from proviral DNA with primers ES7 (5 -CTGTTAA-ATGGCAGTCTAGC-3 ) and ES8 (5 -CACTTCTCCAATTGT-CCCTCA-3 ). Reactions contained 10 mM Tris, pH 8.3; 50 mM KCl; 1.5 mM MgCl 2 ; 600 mM dNTPs; 200 mM of each primer; and 2.0 U AmpliTaq Gold (Perkin-Elmer, Norwalk, CT). Polymerase chain reaction (PCR) amplification was carried out in a PerkinElmer 9600 thermocycler under the following conditions: 95ЊC for 8 min and 98ЊC for 2 min for 1 cycle; 96ЊC for 5 s, 60ЊC for 30 s, and 72ЊC for 2 min for 8 cycles; and 96ЊC for 5 s, 55ЊC for 30 s, and 72ЊC for 2 min for 32 cycles. A 700-bp PCR product was visualized after electrophoresis in 1% agarose gels by ethidium bromide staining.
Radiolabeled HTA probe.
32
P-labeled ES7 -ES8 PCR product was amplified from 0.5 ng of pNL4-3 in a reaction mix containing 3 mM MgCl 2 ; 10 mM Tris-HCl, pH 8.3; 50 mM KCl; 10% glycerol; 30 mM dNTPs; 2.5 U Taq polymerase (Perkin-Elmer); 10 mCi a-32 P-dCTP (3000 mCi/mol); and 200 ng of each primer. PCR amplification was carried out in a Perkin-Elmer TC-1 thermocycler with the following parameters: 90ЊC for 2 min for 1 cycle, followed by 90ЊC for 30 s, 50ЊC for 45 s, and 72ЊC for 1 min for 30 cycles. The radiolabeled pNL4-3 probe was diluted 1:100 before use in the HTA.
HTA. Unlabeled patient PCR product and 32 P-labeled pNL4-3 PCR product were mixed in a 1:1 volumetric ratio in the presence of annealing buffer (0.1 M NaCl; 10 mM Tris-HCl, pH 8.0; 2 mM EDTA). Mixtures were heated to 94ЊC for 2 min, chilled on ice, and resolved on neutral 5% polyacrylamide gels. HTA patterns were visualized by autoradiography.
Sequence analysis. PCR products from 2 patients (patients 32 and 42; table 1) were cloned into pNoTA T7 (5 prime-3 prime, Boulder, CO), according to the manufacturer's instructions. Between 5 and 10 consecutive clones from each PCR reaction were selected for sequence analysis. Cloned DNA was sequenced with AmpliTaqFS and dye-labeled terminators (PE Biosystems, Foster City, CA). Primers used were as follows: ES7 , ES8 , E115 (5 -AGAAAAATTCCCCTCCACAATTAA-3 ), E124 (5 -CCTCAG-GAGGGGACCCAGAAATTG-3 ), and E125 (5 -CAATTTCTG-GGTCCCCTCCTGAGG-3 ). Sequences were aligned against pNL4-3, using Sequencher 3.0 (Gene Codes Corporation, Ann Arbor, MI). Gaps were stripped, and the edited sequences were used to generate a distance matrix. A phylogenetic tree was generated with the neighbor-joining method (Wisconsin Package version 9.1; Genetics Computer Group, Madison, WI). Sequences were submitted to GenBank. The accession numbers are as follows: AF-238572, AF238573, AF238574, AF238575, AF238576, AF238577, AF238578, AF238579, AF238580, AF238581, AF238582, AF238583, AF238584, AF238585, AF238586, AF238587, AF-238588, AF238589, AF238590, AF238591, AF238592, AF238593, JID 2000;182 (July) AF238594, AF238595, AF238596, AF238597, AF238598, AF238599, AF238600, AF238601, AF238602, AF238603, AF-238604, AF238605, AF238606, and AF238607.
Statistics. Comparisons between frequencies of HTA changes in control and NNRTI patients were analyzed with the x 2 test. Comparisons of plasma HIV-1 RNA concentrations between subjects who did or did not have HTA changes were done with the Mann-Whitney test. A P value of !.05 was considered significant.
Results
Forty-nine paired samples were obtained at 1-18-week intervals from 46 patients (14 control patients and 32 NNRTI recipients). Six paired samples were from patients who were receiving no therapy. Eleven paired samples were from patients who were on stable therapy for 16 months with either zidovudine (8 paired samples), didanosine (2 paired samples) or zidovudine plus didanosine plus saquinavir (1 paired sample). Thirty-two paired samples were from patients who had initiated the NNRTIs atevirdine (12 paired samples) or delavirdine (20 paired samples). The mean interval between samples was 8 weeks. The mean CD4 cell count at baseline was 370 cells/mm 3 (range, 15-835 cells/mm 3 ), and the mean virus load was 5.13 log 10 copies/mL (range, 2.20-6.37 copies/mL; table 1).
These samples were analyzed with HTA to estimate the degree of HIV-1 genetic diversity. PCR products amplified from cultured patient PBMC were denatured and then reannealed with a radiolabeled tracking probe derived from pNL4-3. Patient sequences that differed significantly from pNL4-3 formed heteroduplexes that migrated more slowly than pNL4-3 homoduplex (figure 1). Paired samples that had alterations in the banding pattern (the loss, gain, or shift in mobility of a band) between times were considered changed. (table 1) . No significant differences were seen between paired samples from patients on chronic therapy or no therapy and those who had just initiated NNRTIs (9 of 17 paired samples from control patients vs. 14 of 32 from NNRTI patients;
). P 1 . 10 We asked whether sampling time interval, baseline virus load, change in virus load from baseline, or the development of NNRTI-resistant mutants were associated with HTA changes. The median interval between samples was 8 weeks (range, 1-18 weeks) in paired samples with HTA changes and 8 weeks (range, 2-18 weeks) in those paired samples without HTA changes. Baseline virus loads were determined for 29 patients (3 control patients and 26 NNRTI patients). The median baseline virus load of patients who had HTA changes was 4.73 log 10 copies/ mL, and the virus load of patients with no HTA changes was 4.56 log 10 copies/mL (table 1; ). There were 25 patients P = .09 who had RNA levels at baseline and at the time of the second HTA; 10 had HTA changes and 15 did not. The median virus load change for those who had HTA changes was Ϫ4.18 log 10 copies/mL compared with Ϫ4.32 log 10 copies/mL for those who did not ( ) Of 32 patients who received an NNRTI, 27 had P 1 .1 HIV-1 RT sequence analysis performed to detect NNRTI-resistant mutants (table 1) . There was no correlation between development of resistant mutants and HTA pattern changes ( ) .
The heteroduplex patterns among patients were distinct, and all patients had HTA mobilities that were similar at each time, suggesting that the changes seen do not reflect specimen mixup or PCR contamination. To further address the possibility that the apparent changes in HTA patterns represented PCR contamination by either pNL4-3 or other patient samples, phylogenetic analysis of cloned env sequences from patients 42 and 32 were performed. Figure 1D shows a phylogenetic tree comparing pNL4-3 with patients 42 and 32. Distance analysis shows a large genetic difference between pNL4-3 and the clones from patients 42 and 32. This difference makes it unlikely that PCR samples used for HTA analysis represent PCR contamination. Clustering of clones from each patient makes it unlikely that there was cross-contamination between samples.
Discussion
We used HTA to characterize the effect of NNRTI therapy on the evolution of env sequences in HIV-1-infected patients relative to a reference strain. This assay offers a rapid assessment of the degree of HIV-1 genetic divergence within a clinical sample. Because the mobility of a heteroduplex is affected more by insertions or deletions than by base substitutions, this assay may underestimate the degree of genetic diversity present. The most striking finding of this study is that changes in env sequence diversity were frequent and occurred over relatively short periods of time, even in patients who were not on antiretroviral therapies or who were on stable antiretroviral therapies. We found no statistically significant association of factors, such as baseline virus load, change in virus load with therapy, sampling time interval, or development of NNRTIresistant mutants, with the likelihood of HTA changes. Because of the relatively short interval of time between samples, we are unable to determine whether these changes in env quasi species are stable over time.
Our observation that env quasi-species diversity fluctuates in patients who are not on therapy or who are on stable antiretroviral therapy is consistent with other studies. Sequences obtained from a patient on zidovudine showed that env sequences continued to evolve, especially in organs such as brain and lymph node [12] . Gunthard and colleagues [13] found that protease sequences evolved at similar rates to RT sequences, even in patients treated only with RT inhibitors. Gunthard and colleagues [14] have also shown, by sequencing viral clones from patients on suppressive retroviral therapy, that demonstrable evolution of env sequences can occur, even at low levels of viremia. Our study is also consistent with the observation that HIV-1 undergoes high rates of turnover in infected patients [15] . Our finding of env quasi-species instability in untreated patients may reflect selective pressure on HIV-1, either directly on env through neutralizing antibodies, cytotoxic T lymphocyte activity, or chemokine receptor variability or indirectly on viral gene products whose coding sequences are closely linked with env.
These results are in contrast to a previously published study of patients receiving protease inhibitors [3] . In that study, heteroduplex mobility and HTA assays were used to analyze the effect of HIV-1 antiretroviral treatment on env diversification. No changes in HTA patterns were seen in 3 of 3 patients who had not initiated protease therapy or in 9 patients before protease inhibitor therapy was begun. However, once treatment with protease inhibitors failed, env evolution occurred.
There are 4 important differences that could explain why the frequency of changes in our population of patients was higher than that in the study described above [3] . First, in our study, env sequences were amplified from cultured PBMC, whereas in the earlier study, PCR products were amplified from plasma. It is possible that changes in env quasi-species diversity in patients on stable therapy or patients not undergoing therapy are easier to detect when assaying cultured PBMC because selection for replication-competent virus occurs. Second, we studied a significantly larger number of patients (12 patients in their study vs. 46 patients in our study), which may have increased our ability to detect changes in env quasi-species diversity that occur independently of antiretroviral therapy. Third, there may be differences in the frequency of HTA changes because of the differences in the efficacy of protease inhibitors and the NNRTIs used in this study. Although we found no association of change in virus load during therapy with changes in HTA pattern, few patients in our study achieved virus load suppression 400 copies/mL. Fourth, env evolution may be more rapid in some patients (perhaps because of differences in immune responses or chemokine-receptor variation); thus, differences in patient populations could explain differences in the HTA pattern stability among patients off therapy seen in the 2 studies.
It is clear from our study that partially suppressive therapy with some NNRTIs does not decrease the level of evolution that occurs within an individual's quasi species. This finding is in agreement with the work of others [12, 13] . Continued viral evolution may allow HIV-1 to escape immune surveillance and develop resistance to therapy. More studies of patients receiving recommended combination therapies are needed to determine whether NNRTI and protease inhibitors differ in their effects on env diversification.
